Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2026)

Solid Biosciences has reported Cash from Financing Activities for 9 years, with the latest figure at $239.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 25.98% year-over-year to $239.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $243.7 million (up 18.94% YoY) and the FY2025 annual result came in at $194.4 million, up 58.81% from the prior year.
• Cash from Financing Activities climbed to $239.0 million in Q1 2026 per SLDB's latest filing, from $5.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $239.0 million in Q1 2026 and troughed at -$1.6 million in Q2 2025.
• A 5-year average of $45.1 million and a median of $4.1 million in 2024 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 113137.88% in 2022, down 133.33% in 2022.
• Over 5 years, Cash from Financing Activities stood at $74.7 million in 2022, then plunged by 99.32% to $505000.0 in 2023, then surged by 1274.26% to $6.9 million in 2024, then dropped by 25.89% to $5.1 million in 2025, then soared by 4547.62% to $239.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $239.0 million, $5.1 million, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.